GPRC5D as a novel immunotherapeutic target in multiple myeloma

Nature Reviews Clinical Oncology, Published online: 01 February 2023; doi:10.1038/s41571-023-00735-4The development of modern immune-based therapies for multiple myeloma has expanded rapidly over the past several years, and GPRC5D has been identified as a viable immunotherapeutic target. Herein, we discuss data and provide future perspectives on GPRC5D-directed CAR T cells and bispecific antibodies for patients with relapsed and/or refractory multiple myeloma.
Source: Nature Reviews Clinical Oncology - Category: Cancer & Oncology Authors: Source Type: research